Post-treatment anti-Mullerian hormone (AMH) levels predict long-term ovarian dysfunction in women with hematological malignancies

References

• Ehrhardt MJ, Hochberg J, Bjornard KL, et al. Long-term survivors of childhood, adolescent and young adult non-Hodgkin lymphoma. Br J Haematol. 2019;185(6):1099–1110.
   PubMed Web of Science ®Google Scholar
• Bartram J, Veys P, Vora A. Improvements in outcome of childhood acute lymphoblastic leukaemia (ALL) in the UK - a success story of modern medicine through successive UKALL trials and international collaboration. Br J Haematol. 2020;191(4):562–567.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
   PubMed Web of Science ®Google Scholar
• Loren AW. Fertility issues in patients with hematologic malignancies. Hematology Am Soc Hematol Educ Program. 2015;2015:138–145.
   PubMedGoogle Scholar
• Rossi BV, Missmer S, Correia KF, et al. Ovarian reserve in women treated for acute lymphocytic leukemia or acute myeloid leukemia with chemotherapy, but not stem cell transplantation. ISRN Oncol. 2012;2012:956190.
   PubMedGoogle Scholar
• Green DM, Sklar CA, Boice, Jr. JD, et al. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol. 2009;27(14):2374–2381.
   PubMed Web of Science ®Google Scholar
• Wo JY, Viswanathan AN. Impact of radiotherapy on fertility, pregnancy, and neonatal outcomes in female cancer patients. Int J Radiat Oncol Biol Phys. 2009;73(5):1304–1312.
   PubMed Web of Science ®Google Scholar
• Molina JR, Barton DL, Loprinzi CL. Chemotherapy-induced ovarian failure: manifestations and management. Drug Saf. 2005;28(5):401–416.
   PubMed Web of Science ®Google Scholar
• Lower EE, Blau R, Gazder P, et al. The risk of premature menopause induced by chemotherapy for early breast cancer. J Womens Health Gend Based Med. 1999;8(7):949–954.
   PubMedGoogle Scholar
• Gargus E, Deans R, Anazodo A, et al. Management of primary ovarian insufficiency symptoms in survivors of childhood and adolescent cancer. J Natl Compr Canc Netw. 2018;16(9):1137–1149.
   PubMed Web of Science ®Google Scholar
• Peigné M, Decanter C. Serum AMH level as a marker of acute and long-term effects of chemotherapy on the ovarian follicular content: a systematic review. Reprod Biol Endocrinol. 2014;12:26.
   PubMed Web of Science ®Google Scholar
• Li X, Liu S, Ma L, et al. Can anti-Müllerian hormone Be a reliable biomarker for assessing ovarian function in women postchemotherapy? Cancer Manag Res. 2020;12:8171–8181.
   PubMed Web of Science ®Google Scholar
• Miyoshi Y, Ohta H, Namba N, et al. Low serum concentrations of anti-Müllerian hormone are common in 53 female childhood cancer survivors. Horm Res Paediatr. 2013;79(1):17–21.
   PubMed Web of Science ®Google Scholar
• Josso N, Clemente N. Transduction pathway of anti-Müllerian hormone, a sex-specific member of the TGF-beta family. Trends Endocrinol Metab. 2003;14(2):91–97.
   PubMed Web of Science ®Google Scholar
• Moolhuijsen LME, Visser JA. Anti-Müllerian hormone and ovarian reserve: update on assessing ovarian function. J Clin Endocrinol Metab. 2020;105(11):3361–3373.
   PubMed Web of Science ®Google Scholar
• Durlinger AL, Kramer P, Karels B, et al. Control of primordial follicle recruitment by anti-Müllerian hormone in the mouse ovary. Endocrinology. 1999;140(12):5789–5796.
   PubMed Web of Science ®Google Scholar
• Durlinger AL, Gruijters MJ, Kramer P, et al. Anti-Müllerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology. 2001;142(11):4891–4899.
   PubMed Web of Science ®Google Scholar
• Fanchin R, Schonäuer LM, Righini C, et al. Serum anti-Müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod. 2003;18(2):323–327.
   PubMed Web of Science ®Google Scholar
• Bhide P, Pundir J, Homburg R, et al. Biomarkers of ovarian reserve in childhood and adolescence: A systematic review. Acta Obstet Gynecol Scand. 2019;98(5):563–572.
   PubMed Web of Science ®Google Scholar
• Lawrenz B, Fehm T, von Wolff M, et al. Reduced pretreatment ovarian reserve in premenopausal female patients with Hodgkin lymphoma or non-Hodgkin-lymphoma–evaluation by using antimüllerian hormone and retrieved oocytes. Fertil Steril. 2012;98(1):141–144.
   PubMed Web of Science ®Google Scholar
• Decanter C, Morschhauser F, Pigny P, et al. Anti-Müllerian hormone follow-up in young women treated by chemotherapy for lymphoma: preliminary results. Reprod Biomed Online. 2010;20(2):280–285.
   PubMed Web of Science ®Google Scholar
• Martin HL, Ullah S, Abbas N, et al. Predicting chemotherapy-induced menopause using baseline and post-chemotherapy anti-Müllerian hormone levels: results of a pilot study. Cancer Reports (Hoboken, N.J.). 2021;4(3):e1342–e1342.
   PubMedGoogle Scholar
• Krawczuk-Rybak M, Leszczynska E, Poznanska M, et al. Anti-müllerian hormone as a sensitive marker of ovarian function in young cancer survivors. Int J Endocrinol. 2013;2013:125080–125080.
   PubMed Web of Science ®Google Scholar
• van Beek RD, van den Heuvel-Eibrink MM, Laven JS, et al. Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for hodgkin's lymphoma during childhood. J Clin Endocrinol Metab. 2007;92(10):3869–3874.
   PubMed Web of Science ®Google Scholar
• Lekovich J, Lobel ALS, Stewart JD, et al. Female patients with lymphoma demonstrate diminished ovarian reserve even before initiation of chemotherapy when compared with healthy controls and patients with other malignancies. J Assist Reprod Genet. 2016;33(5):657–662.
   PubMed Web of Science ®Google Scholar
• Lie Fong S, Lugtenburg PJ, Schipper I, et al. Anti-müllerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies. Hum Reprod. 2008;23(3):674–678.
   PubMed Web of Science ®Google Scholar
• Kimler BF, Briley SM, Johnson BW, et al. Radiation-induced ovarian follicle loss occurs without overt stromal changes. Reproduction (Cambridge, England). 2018;155(6):553–562.
   PubMed Web of Science ®Google Scholar
• Bedoschi G, Navarro PA, Oktay K. Chemotherapy-induced damage to ovary: mechanisms and clinical impact. Future Oncol. 2016;12(20):2333–2344.
   PubMed Web of Science ®Google Scholar
• Nakano H, Ashizawa M, Akahoshi Y, et al. Assessment of the ovarian reserve with anti-Müllerian hormone in women who underwent allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning regimens or myeloablative regimens with ovarian shielding. Int J Hematol. 2016;104(1):110–116.
   PubMed Web of Science ®Google Scholar
• Ashizawa M, Akahoshi Y, Nakano H, et al. Updated clinical outcomes of hematopoietic stem cell transplantation using myeloablative total body irradiation with ovarian shielding to preserve fertility. Biol Blood Marrow Transplant. 2019;25(12):2461–2467.
   PubMed Web of Science ®Google Scholar
• Nakano H, Ashizawa M, Akahoshi Y, et al. Assessment of the ovarian reserve with anti-Müllerian hormone in women who underwent allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning regimens or myeloablative regimens with ovarian shielding. Int J Hematol. 2016;104(1):110–116.
   PubMed Web of Science ®Google Scholar
• Armuand GM, Rodriguez-Wallberg KA, Wettergren L, et al. Sex differences in fertility-related information received by young adult cancer survivors. J Clin Oncol. 2012;30(17):2147–2153.
   PubMed Web of Science ®Google Scholar
• Feng C, Lai Y, Li R, et al. Reproductive health in Southeast Asian women: current situation and the influence factors. Global Health Journal. 2018;2(1):32–41.
   Google Scholar
• Gorman JR, Su HI, Roberts SC, et al. Experiencing reproductive concerns as a female cancer survivor is associated with depression. Cancer. 2015;121(6):935–942.
   PubMed Web of Science ®Google Scholar